U.S. markets close in 6 hours 23 minutes
  • S&P 500

    4,167.32
    -6.53 (-0.16%)
     
  • Dow 30

    34,361.68
    -20.45 (-0.06%)
     
  • Nasdaq

    13,365.82
    -64.16 (-0.48%)
     
  • Russell 2000

    2,224.63
    +53.68 (+2.47%)
     
  • Crude Oil

    65.55
    +0.18 (+0.28%)
     
  • Gold

    1,850.80
    +12.70 (+0.69%)
     
  • Silver

    27.65
    +0.28 (+1.02%)
     
  • EUR/USD

    1.2151
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.6400
    +0.0050 (+0.31%)
     
  • GBP/USD

    1.4111
    +0.0009 (+0.06%)
     
  • USD/JPY

    109.1600
    -0.1870 (-0.17%)
     
  • BTC-USD

    44,784.59
    -3,929.14 (-8.07%)
     
  • CMC Crypto 200

    1,241.55
    +43.63 (+3.64%)
     
  • FTSE 100

    7,019.71
    -23.90 (-0.34%)
     
  • Nikkei 225

    27,824.83
    -259.67 (-0.92%)
     

UPDATE 1-U.S. begins study on allergic reaction risk in Moderna, Pfizer vaccines

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Adds details of trial)

April 7 (Reuters) - The U.S. National Institutes of Health said on Wednesday it had begun a mid-stage study to determine the risk of allergic reactions to COVID-19 vaccines made by Moderna Inc and Pfizer Inc.

Several allergic reaction incidents, including serious episodes, known as anaphylaxis, have been reported in the U.S. after vaccinations of Pfizer/BioNTech and Moderna shots.

In January, the U.S. Centers for Disease Control and Prevention said allergic reactions are occurring at a rate of 11.1 per 1 million vaccinations.

The study, funded by the National Institute of Allergy and Infectious Diseases, will enroll 3,400 adults between the ages of 18 to 69, with about 60% participants having a history of severe allergic reactions to food, insect stings or immunotherapy.

The goal of the trial is to access the proportion of participants who have a systemic allergic reaction within 90 minutes after injection.

The agency expects to report data later this summer.

(Reporting by Manas Mishra and Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli, Bernard Orr)